Clinical Trial

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)

Study acronym: Peds IMPACT
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse Intrinsic Pontine Glioma (ndDIPG)
Protocol Amendment History 3 changes
critical Trial status changed: Active, Not Recruiting → Not Yet Recruiting 2026-05-23
notable Enrollment increased: 18 -> 24 participants 2026-05-23
minor Trial arms changed: 1 -> 3 2026-05-23
Trial Details
NCT Number NCT06946680
Lead Sponsor University of Florida
Collaborators: Florida Department of Health, Live Like Bella, St. Baldrick's Foundation, American Brain Tumor Association
Conditions High-grade Glioma, Diffuse Intrinsic Pontine Glioma
Enrollment 24 participants
Start Date 2026-07
Primary Completion 2030-12 (estimated)
Study Completion 2045-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01